Vitamin A-Containing Intranasal Drops Improve Odour Detection Threshold
Authors:
- Katherine L. WhitcroftKWKatherine L. Whitcroft
- Melanie E. DietzMDMelanie E. Dietz
- Antje HaehnerAHAntje Haehner
- Thomas HummelTHThomas Hummel
Open Access
- 8 July 2026
- journal article
- Published by S. Karger AG in ORL
- p. 1-8
Abstract
Introduction: Retinoic acid, a metabolite of vitamin A (VA), has been shown in animal work to support olfactory receptor neuron regeneration. A limited amount of clinical research has also demonstrated potential therapeutic benefit in patients with olfactory dysfunction (OD). We therefore performed, to our knowledge, the first prospective study investigating whether the intranasal VA-containing “Coldastop” is beneficial in treating patients with non-sinonasal OD. Methods: A non-blinded prospective comparative study was performed, in patients with OD due to post-infectious, post-traumatic, and idiopathic aetiologies. Patients were treated with olfactory training (OT) alone, OT plus intranasal VA (Coldastop, OT+VA), or OT plus intranasal steroids (mometasone furoate, OT+S) for 12 weeks. Full psychophysical olfactory testing was performed before and after treatment using the “Sniffin’ Sticks” test battery (with results for odour threshold, discrimination, identification, and composite “TDI”). Results: A total of 144 patients completed the study: 52 OT, 42 OT+S, 50 OT+VA. The majority of patients had post-infective OD. There were no significant differences between groups in age/sex. There were statistically significant improvements in each subtest (T/D/I) and composite scores (TDI) within each treatment regimen. Across groups, there was a significant interaction between treatment and time (controlling for baseline characteristics) for odour threshold, F(2, 139) = 3.2, p = 0.044, with the largest improvement being seen in the OT+VA group. Further, the greatest proportion of patients reached clinically significant improvement within the OT+VA group (T/D/I/TDI), but this did not reach statistical significance. Conclusion: Intranasal VA may be of benefit in treating OD. Further large-scale randomised trials are required.Keywords
This publication has 34 references indexed in Scilit:
- Use of platelet‐rich plasma for COVID‐19–related olfactory loss: a randomized controlled trialInternational Forum of Allergy & Rhinology, 2022
- Olfactory Dysfunction in COVID-19JAMA, 2020
- Patterns of olfactory impairment reflect underlying disease etiologyThe Laryngoscope, 2016
- Use of olfactory training in post‐traumatic and postinfectious olfactory dysfunctionThe Laryngoscope, 2013
- Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: A double‐blind, placebo‐controlled, randomized clinical trialThe Laryngoscope, 2012
- Effects of olfactory training in patients with olfactory lossThe Laryngoscope, 2009
- Vitamin A deficiency leads to increased cell proliferation in olfactory epithelium of mature ratsJournal of Neurobiology, 2003
- Neural regeneration and the peripheral olfactory systemThe Anatomical Record, 2002
- Retinoic Acid Biosynthetic Activity and Retinoid Receptors in the Olfactory Mucosa of Adult MiceBiochemical and Biophysical Research Communications, 1999
- Treatment of Uncomplicated Anosmia by Vitamin AJAMA Otolaryngology–Head & Neck Surgery, 1962